McMillan Shakespeare Ltd
MMS: XASX (AUS)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| LOCK|.@s | LOCK|@%? | LOCK|&$B^tT# |
McMillan Shakespeare Earnings: Executing Well but Fighting Margin Pressure
McMillan Shakespeare's first-half fiscal 2026 NPAT before impact of acquisitions and divestment-related items was flat at AUD 50 million. Revenue was up 11% while EBITDA grew 5%. Dividend payouts reduced to 85% of UNPATA from 100%, though the firm declared a AUD 10 million buyback. Shares fell 5%.
